PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
2.39
Net debt aligned with Biotechnology median of 2.32. David Dodd would verify if industry standard leverage is appropriate given business cyclicality.
No Data
No Data available this quarter, please select a different quarter.
3.68
Current ratio 75-90% of Biotechnology median of 4.56. John Neff would demand higher margins to compensate for tighter liquidity.
No Data
No Data available this quarter, please select a different quarter.